PRESS RELEASE published on 01/24/2024 at 14:36, 1 year 10 months ago Alternative Wellness Health Enters the Hydrogen Water Vertical Market Alternative Wellness Health, Inc. has announced the launch of a new product, Amethyst HYDRO, for the hydrogen premium water vertical market. The product features a patented hydrogen infusing process with 2.5 PPM and the addition of Fulvic Acid and Aloe Vera, targeting health-conscious consumers. The company aims to capitalize on marketing opportunities and expand its presence in wellness salons, positioning the product as an innovative and healthy energy drink alternative. With a focus on providing great taste and health benefits, the company plans to include CBD and unique flavoring in future products. Alternative Wellness Health, Inc. (EXMT) is a manufacturing and marketing company involved in the sales and marketing of CBD Health products and software applications, aiming to lead in innovative technologies and manufacturing sectors. Amethyst HYDRO Hydrogen Premium Water Fulvic Acid Aloe Vera CBD Health Products
Published on 12/05/2025 at 02:35, 4 hours 2 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 37 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 32 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 37 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 7 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 47 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 12 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 22 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 27 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 23 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL